On August 25, Lepu Medical(300003) announced that its holding subsidiary, Minwei Bio, independently developed an innovative drugMWN109 injection is currently undergoing Phase II clinical trials for the treatment of overweight or obesity, and the first subject was successfully dosed recently.

The drug is a GLP-1/GIP/GCG receptor triple agonist with global intellectual property rights .MWN109 injection is designed to effectively control blood sugar and reduce weight by stimulating pancreatic beta cells to secrete insulin and increase satiety. MWN109 injection received clinical trial approval from the National Medical Products Administration in November 2024. A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial has been initiated, primarily investigating the effectiveness of different doses of MWN109 injection in reducing weight over a 24-week period in non-diabetic overweight or obese participants.

The primary endpoint of the study is the percentage change in body weight compared to baseline after 24 weeks of dosing. The company reminds investors that this project is still in the early stages of research and development, and subsequent clinical trials are subject to uncertainty and risks.

By mid-2025, Lepu Medical achieved revenue of 3.369 billion yuan and net profit attributable to shareholders of the parent company of 691 million yuan.

https://finance.eastmoney.com/a/202508263494829540.html